<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04127981</url>
  </required_header>
  <id_info>
    <org_study_id>ONJ2018-002</org_study_id>
    <nct_id>NCT04127981</nct_id>
  </id_info>
  <brief_title>Medical Imaging of Cachexia</brief_title>
  <official_title>A Pilot Bioimaging Trial of Cancer Cachexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olivia Newton-John Cancer Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>La Trobe University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Austin Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Olivia Newton-John Cancer Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot trial using 18F‐FDG PET and DXA scans to determine whether these
      investigations are objective tools to assess cachexia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study will establish the differences in BAT uptake of 18F‐FDG in cachectic and
      non‐cachectic cancer patients using PET imaging.

      Patients willbe assessed for sarcopenia using a dual energy X‐ray absorptiometry or bone
      densitometry scan (DXA). Given the variables which may affect uptake of BAT in cancer
      patients, this study will standardise patient preparation and PET scan procedure in order to
      obtain the most reliable assessment of BAT activity in all patients on study.

      It is hypothesisd that use of this PET imaging technique, which is part of standard care to
      assess cancer progression, may assist clinicians in early identification of metabolic changes
      in a patient, with potential for early intervention and utility in monitoring success of
      treatments of cachexia.

      A total of 40 patients will be evaluated, 20 patients with advanced/metastatic colorectal,
      non‐small cell lung cancer (NSCLC) or pancreatic cancer without cachexia, and 20 patients
      with advanced/metastatic colorectal, non‐small cell lung cancer (NSCLC), or pancreatic cancer
      with documented cachexia, all of whom are referred for standard of care 18F‐FDG PET scans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Anticipated">March 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>20 patients with advanced/metastatic colorectal, non‐small cell lung cancer (NSCLC) or pancreatic cancer without cachexia, and 20 patients with advanced/metastatic colorectal, non‐small cell lung cancer (NSCLC), or pancreatic cancer with documented cachexia</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of a clinical diagnosis of cachexia with the metabolic activity of brown adipose tissue, bone density and muscle mass.</measure>
    <time_frame>7 days post enrollment</time_frame>
    <description>Quantitation of the metabolic activity of brown adipose tissue, bone density and muscle mass using 18F‐FDG uptake and bone densitometry will be correlated with a diagnosis of clinical cachexia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimization of PET scanning methods for imaging of brown adipose tissue.</measure>
    <time_frame>7 days post enrollment</time_frame>
    <description>Optimization of the patient environment (ie. ambient temperature) and metabolic state (ie. Heart rate, dietary state) to minimize the impact of these factors and allow direct comparison of metabolic activity of brown adipose tissue between cachectic and non-cachectic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To quantify change from normal of inflammatory blood biomarkers</measure>
    <time_frame>7 days post enrollment</time_frame>
    <description>To validate change from normal laboratory range of inflammatory blood based proteins and enzymes in cachectic vs non-cachectic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To quantify change from normal of immune blood biomarkers</measure>
    <time_frame>7 days post enrollment</time_frame>
    <description>To validate change from normal laboratory range immune blood based proteins and enzymes in cachectic vs non-cachectic patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cancer Cachexia</condition>
  <arm_group>
    <arm_group_label>Patients with cancer cachexia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients with advanced/metastatic colorectal, non‐small cell lung cancer (NSCLC), or pancreatic cancer with documented cachexia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without cancer cachexia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients with advanced/metastatic colorectal, non‐small cell lung cancer (NSCLC) or pancreatic cancer without cachexia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-FDG PET + Dexa Scan</intervention_name>
    <description>18F-FDG PET will be compared with Dexa Scan result within and between arms.</description>
    <arm_group_label>Patients with cancer cachexia</arm_group_label>
    <arm_group_label>Patients without cancer cachexia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with malignant disease;

          -  ECOG Performance score of 0‐2;

          -  Age ≥ 18 years;

          -  Life expectancy of &gt;4 months at screening;

          -  Cachexia patient group only: Fulfils diagnostic criteria for cachexia: unintentional
             weight loss more than 5% over the previous 6 months, or more than 2% in individuals
             with a decreased body‐mass index of &lt;20kg/m2, or skeletal muscle wasting (sarcopenia).

        Exclusion Criteria:

        Patients with uncontrolled Diabetes Mellitus;

          -  Psychological unstable persons presumed unfit to perform the investigations;

          -  Persons unable to lie or sit still for 1‐2 hours;

          -  Pregnant patients;

          -  Patients who received high doses of radiotherapeutic radiation of the neck and/or
             upper chest in their medical history limiting nutritional intake;

          -  Patients who are receiving any chemotherapeutic agents which is limiting nutritional
             intake;

          -  Persons that received cervical or thoracic sympathectomy or have a nerve dysfunction
             which is likely to influence sympathetic nerves;

          -  The use of medication that influences the sympathetic nerve system: ß‐blockers,
             α‐blockers, central anti‐hypertensives, certain anti‐depression drugs (MAO inhibitors,
             tricyclic antidepressives), reserpine, cocaine, calcium channel blockers, labetalol,
             and certain tranquillizers (fenothiazines).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew M Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin Health/ONJCRI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jodie Palmer, PhD</last_name>
    <phone>0394963573</phone>
    <email>jodie.palmer@onjcri.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fiona Scott</last_name>
    <phone>0394963335</phone>
    <email>fiona.scott@onjcri.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3078</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Sze Ting, MBBS, PhD</last_name>
      <phone>+61394969925</phone>
      <email>szeting.lee@austin.org.au</email>
    </contact>
    <investigator>
      <last_name>Hui Gan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Scott</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sze Ting Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>18F-FDG PET Scan</keyword>
  <keyword>Dexa Scan</keyword>
  <keyword>Quality of Life assessment tools</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Cohort data will be shared via journal and conference presentations</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

